Abstract 1172P
Background
While immunotherapy has improved the prognosis of metastatic melanoma patients, a minority of patients will have prolonged remission. Recent data have emphasized the role of the gut microbiome in response to immunotherapy; however, there is a discrepancy in defining the optimal microbiome. Although recent fecal microbial transplantation (FMT) trials only included patients with sustained response to immunotherapy, a mixed response was registered, with scarce data on the antimicrobial resistance of the donors. A thorough evaluation of the gut microbiome of potential FMT donors is warranted before future trials.
Methods
A shotgun metagenomic sequencing was performed on Illumina NextSeq 2000 platform on stool samples of metastatic melanoma patients with complete and sustained response to immunotherapy (N=15).
Results
The average age of patients was 61.0 (±12.2) years. Patients usually received immunotherapy in the first line (N=14, 93.3%), with an average time to complete response of 7.6 (± 4.6) months. Firmicutes were the most common phylum with a relative abundance of 62.1% ± 13.2, followed by the Bacteroidetes (31.7% ± 13.8). Protobacteria were present in all patients, ranging from 0.06-3.4%. On Class level, Clostridia were the most abundant (53.9% ± 10.4), followed by Bacteroidia (31.7% ± 13.8). Similar results were seen for the order level, while Lachnospiraceae were the most common family (30.2% ± 8.6) but ranged from 8.1 – 43.8%, followed by Ruminococcaceae (6.7% ± 14.0), and Bacteroidaceae (6.2% ± 11.6). Only 14 bacterial families were present in all patients (25.4%). On the genus level, Bacteroides had the highest relative abundance (11.6% ± 6.2), followed by Lachnospiraceae (10.1% ± 5.9), and Phocaeicola (6.2% ± 4.4). 377 different species were found, with six patients (40%) reporting no traces of the Akkermansia municiphila. Antimicrobial resistance was most commonly found for tetracyclines (63.3% ± 6.9), macrolide-lincosamine-streptogramin B (14.5% ± 7.9), and sulfonamide trimethoprim (4.4% ± 2.4).
Conclusions
Patients with complete and sustained response to immunotherapy exhibit a heterogeneous gut microbiome with common resistance to Tetracycline antibiotics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Croatian Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13